Document is current
Any future updates will be listed below
-
Authors
Hu, Wei https://orcid.org/0000-0002-0392-6939
Dolsten, Gabriel A.
Wang, Eric Y. https://orcid.org/0000-0002-6120-5136
Beroshvili, Giorgi
Wang, Zhong-Min
Ghelani, Aazam P.
Uhl, Lion F. K.
Bou-Puerto, Regina https://orcid.org/0000-0002-7546-3312
Huang, Xiao
Michaels, Anthony J.
Hoyos, Beatrice E.
Jin, Wenjie https://orcid.org/0000-0002-7527-6357
Pritykin, Yuri https://orcid.org/0000-0001-6589-981X
Rudensky, Alexander Y. https://orcid.org/0000-0003-1280-2898
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA008748)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (AI034206)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (DP2AI171161)
Ludwig Institute for Cancer Research
- License Information
-
More Information
Article History
Received: 5 May 2025
Accepted: 3 September 2025
First Online: 8 October 2025
Competing interests
: A.Y.R. is a Scientific Advisory Board member and has equity in Sonoma Biotherapeutics, RAPT Therapeutics, Coherus BioSciences, Santa Ana Bio, Odyssey Therapeutics, Nilo Therapeutics and Vedanta Biosciences; he is also a Scientific Advisory Board member of BioInvent and Amgen and a co-inventor of a CCR8 + T reg cell depletion IP licensed to Takeda, which is unrelated to the content of this publication. Z.-M.W. is an employee of Genentech, which is unrelated to the content of this publication. The other authors declare no competing interests.
